2024 Q2 Form 10-K Financial Statement
#000121390024028577 Filed on April 01, 2024
Income Statement
Concept | 2024 Q2 | 2023 Q4 | 2023 |
---|---|---|---|
Revenue | $125.0K | $42.71K | $253.6K |
YoY Change | 109.92% | -91.65% | -50.4% |
Cost Of Revenue | $89.56K | $146.3K | $474.6K |
YoY Change | -51.32% | -66.17% | 9.76% |
Gross Profit | $35.41K | -$103.6K | -$221.0K |
YoY Change | -128.45% | -231.34% | -380.29% |
Gross Profit Margin | 28.33% | -242.45% | -87.15% |
Selling, General & Admin | $1.130M | $1.690M | $4.242M |
YoY Change | 144.07% | 29.66% | 225.36% |
% of Gross Profit | 3190.13% | ||
Research & Development | $3.095M | $100.2K | $691.8K |
YoY Change | 1418.27% | -80.93% | 31.63% |
% of Gross Profit | 8741.88% | ||
Depreciation & Amortization | $1.536K | $10.42K | $50.32K |
YoY Change | -77.74% | 12.77% | 53.56% |
% of Gross Profit | 4.34% | ||
Operating Expenses | $4.225M | $1.791M | $4.934M |
YoY Change | 533.73% | -2.11% | 169.7% |
Operating Profit | -$4.189M | -$1.894M | -$5.155M |
YoY Change | 431.57% | 8.21% | 194.47% |
Interest Expense | -$4.720K | -$138.1K | -$2.724M |
YoY Change | -100.43% | -96.94% | -39.53% |
% of Operating Profit | |||
Other Income/Expense, Net | $19.68K | -$13.95K | $5.296M |
YoY Change | -101.85% | -67.74% | -12348.27% |
Pretax Income | -$4.174M | -$2.046M | -$3.814M |
YoY Change | 24.83% | -66.88% | -38.26% |
Income Tax | $438.00 | $60.00 | $250.00 |
% Of Pretax Income | |||
Net Earnings | -$4.173M | -$2.131M | -$3.986M |
YoY Change | 25.06% | -65.52% | -35.51% |
Net Earnings / Revenue | -3338.95% | -4990.54% | -1572.12% |
Basic Earnings Per Share | -$4.23 | -$0.99 | |
Diluted Earnings Per Share | -$4.23 | -$0.37 | -$1.01 |
COMMON SHARES | |||
Basic Shares Outstanding | 11.57M shares | 5.800M shares | 3.960M shares |
Diluted Shares Outstanding | 1.015M shares | 3.960M shares |
Balance Sheet
Concept | 2024 Q2 | 2023 Q4 | 2023 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $1.577M | $2.142M | $2.142M |
YoY Change | 8167.44% | 708.88% | 708.88% |
Cash & Equivalents | $1.577M | $2.142M | $2.142M |
Short-Term Investments | |||
Other Short-Term Assets | $1.464M | $4.403M | $4.403M |
YoY Change | -71.09% | 1533.01% | 1533.01% |
Inventory | $426.0K | $466.2K | $466.2K |
Prepaid Expenses | |||
Receivables | $296.4K | $231.3K | $231.3K |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $3.763M | $7.243M | $7.243M |
YoY Change | -33.69% | 559.02% | 559.02% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $159.6K | $71.28K | $71.28K |
YoY Change | 2028.45% | 109.96% | 109.96% |
Goodwill | |||
YoY Change | |||
Intangibles | $250.1K | $227.3K | |
YoY Change | 21.19% | 38.36% | |
Long-Term Investments | |||
YoY Change | |||
Other Assets | $404.5K | $242.7K | $242.7K |
YoY Change | -71.73% | ||
Total Long-Term Assets | $564.1K | $541.2K | $541.2K |
YoY Change | -66.5% | 173.03% | 173.03% |
TOTAL ASSETS | |||
Total Short-Term Assets | $3.763M | $7.243M | $7.243M |
Total Long-Term Assets | $564.1K | $541.2K | $541.2K |
Total Assets | $4.327M | $7.784M | $7.784M |
YoY Change | -41.2% | 500.04% | 500.04% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $643.4K | $506.2K | $506.2K |
YoY Change | -39.21% | -33.28% | -33.28% |
Accrued Expenses | $13.65K | $13.65K | |
YoY Change | 5.0% | 5.0% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | -100.0% | ||
Long-Term Debt Due | $8.772K | $8.770K | $8.770K |
YoY Change | -98.42% | -99.96% | -99.96% |
Total Short-Term Liabilities | $1.219M | $2.835M | $2.835M |
YoY Change | -95.78% | -88.15% | -88.15% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $148.7K | $150.3K | $150.3K |
YoY Change | -99.4% | -88.17% | -88.17% |
Other Long-Term Liabilities | $0.00 | $0.00 | |
YoY Change | -100.0% | -100.0% | |
Total Long-Term Liabilities | $148.7K | $150.3K | $150.3K |
YoY Change | -89.17% | -90.15% | -90.15% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $1.219M | $2.835M | $2.835M |
Total Long-Term Liabilities | $148.7K | $150.3K | $150.3K |
Total Liabilities | $1.368M | $2.914M | $2.914M |
YoY Change | -95.48% | -88.29% | -88.29% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$36.32M | -$32.58M | |
YoY Change | 4.52% | 13.07% | |
Common Stock | $102.00 | $581.00 | |
YoY Change | -57.14% | 143.1% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $3.035M | $4.870M | $4.870M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $4.327M | $7.784M | $7.784M |
YoY Change | -41.2% | 500.04% | 500.04% |
Cashflow Statement
Concept | 2024 Q2 | 2023 Q4 | 2023 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$4.173M | -$2.131M | -$3.986M |
YoY Change | 25.06% | -65.52% | -35.51% |
Depreciation, Depletion And Amortization | $1.536K | $10.42K | $50.32K |
YoY Change | -77.74% | 12.77% | 53.56% |
Cash From Operating Activities | -$1.188M | -$63.67K | -$4.543M |
YoY Change | 279.03% | -3.5% | 349.8% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $130.6K | $66.56K | $115.9K |
YoY Change | 620.13% | 13.51% | 92.73% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | -$130.6K | -$66.56K | -$115.9K |
YoY Change | 620.13% | 13.51% | 92.73% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $7.586M | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -860.0 | 0.000 | 6.475M |
YoY Change | -100.27% | -100.0% | 429.96% |
NET CHANGE | |||
Cash From Operating Activities | -1.188M | -63.67K | -4.543M |
Cash From Investing Activities | -130.6K | -66.56K | -115.9K |
Cash From Financing Activities | -860.0 | 0.000 | 6.475M |
Net Change In Cash | -1.320M | -130.2K | 1.816M |
YoY Change | 12408.34% | -32.61% | 1097.74% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$1.188M | -$63.67K | -$4.543M |
Capital Expenditures | $130.6K | $66.56K | $115.9K |
Free Cash Flow | -$1.319M | -$130.2K | -$4.659M |
YoY Change | 297.68% | 4.5% | 335.36% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
3960280 | shares |
CY2023 | dei |
Document Type
DocumentType
|
10-K | |
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-41719 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
60 DEGREES PHARMACEUTICALS, INC. | |
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
45-2406880 | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1025 Connecticut Avenue | |
CY2023 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
NW Suite 1000 | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Washington, D.C | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
WA | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20036 | |
CY2023 | dei |
City Area Code
CityAreaCode
|
(202) | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
327-5422 | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2023 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q3 | dei |
Entity Public Float
EntityPublicFloat
|
11551806 | usd |
CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
11570578 | shares |
CY2023 | dei |
Auditor Name
AuditorName
|
RBSM LLP | |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
587 | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
Las Vegas, Nevada | |
CY2023Q4 | us-gaap |
Cash
Cash
|
2142485 | usd |
CY2022Q4 | us-gaap |
Cash
Cash
|
264865 | usd |
CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
231332 | usd |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
45965 | usd |
CY2023Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
4402602 | usd |
CY2022Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
200967 | usd |
CY2022Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
68629 | usd |
CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
466169 | usd |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
518578 | usd |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
7242588 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1099004 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
57761 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
21300 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
13517 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
12647 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
242647 | usd |
CY2023Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
227258 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
164255 | usd |
CY2023Q4 | us-gaap |
Other Assets
OtherAssets
|
483422 | usd |
CY2022Q4 | us-gaap |
Other Assets
OtherAssets
|
176902 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
7783771 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
1297206 | usd |
CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
506206 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
758668 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
13650 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
13000 | usd |
CY2022Q4 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
325000 | usd |
CY2022Q4 | sxtp |
Related Party Notes Netincluding Accrued Interest
RelatedPartyNotesNetincludingAccruedInterest
|
195097 | usd |
CY2022Q4 | us-gaap |
Other Long Term Debt Current
OtherLongTermDebtCurrent
|
4276609 | usd |
CY2023Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Current
SBAEIDLincludingAccruedInterestCurrent
|
8772 | usd |
CY2022Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Current
SBAEIDLincludingAccruedInterestCurrent
|
2750 | usd |
CY2022Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
16855887 | usd |
CY2023Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
2306796 | usd |
CY2022Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
1129840 | usd |
CY2022Q4 | sxtp |
Derivative Liabilities Related Parties
DerivativeLiabilitiesRelatedParties
|
364360 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2835424 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
23921211 | usd |
CY2022Q4 | us-gaap |
Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
|
255000 | usd |
CY2023Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Non Current
SBAEIDLincludingAccruedInterestNonCurrent
|
150251 | usd |
CY2022Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Non Current
SBAEIDLincludingAccruedInterestNonCurrent
|
160272 | usd |
CY2022Q4 | us-gaap |
Senior Long Term Notes
SeniorLongTermNotes
|
1109783 | usd |
CY2023Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
150251 | usd |
CY2022Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
1525055 | usd |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
2985675 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
25446266 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
78803 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
78803 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
9858040 | usd |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
581 | usd |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
239 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
27456802 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
5164461 | usd |
CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
135561 | usd |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
73708 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-32580850 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-28815148 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4870134 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-23576740 | usd |
CY2023Q4 | us-gaap |
Minority Interest
MinorityInterest
|
-72038 | usd |
CY2022Q4 | us-gaap |
Minority Interest
MinorityInterest
|
-572320 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
4798096 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-24149060 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
7783771 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1297206 | usd |
CY2023 | us-gaap |
Revenues
Revenues
|
253573 | usd |
CY2022 | us-gaap |
Revenues
Revenues
|
223208 | usd |
CY2023 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
474550 | usd |
CY2022 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
432370 | usd |
CY2023 | us-gaap |
Gross Profit
GrossProfit
|
-220977 | usd |
CY2022 | us-gaap |
Gross Profit
GrossProfit
|
-209162 | usd |
CY2022 | us-gaap |
Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
|
288002 | usd |
CY2023 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-220977 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
78840 | usd |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
691770 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
525563 | usd |
CY2023 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4241836 | usd |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1303722 | usd |
CY2023 | us-gaap |
Operating Expenses
OperatingExpenses
|
4933606 | usd |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
1829285 | usd |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5154583 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1750445 | usd |
CY2023 | us-gaap |
Interest Expense
InterestExpense
|
2286637 | usd |
CY2022 | us-gaap |
Interest Expense
InterestExpense
|
3989359 | usd |
CY2023 | us-gaap |
Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
|
-399725 | usd |
CY2022 | us-gaap |
Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
|
-504613 | usd |
CY2023 | us-gaap |
Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
|
-37278 | usd |
CY2022 | us-gaap |
Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
|
-10312 | usd |
CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-1231480 | usd |
CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
120683 | usd |
CY2023 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
5379269 | usd |
CY2023 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-83116 | usd |
CY2022 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-43238 | usd |
CY2023 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
1341033 | usd |
CY2022 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-4426839 | usd |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3813550 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6177284 | usd |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
250 | usd |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
500 | usd |
CY2023 | us-gaap |
Profit Loss
ProfitLoss
|
-3813800 | usd |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-6177784 | usd |
CY2023 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-48098 | usd |
CY2022 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
3936 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3765702 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6181720 | usd |
CY2023 | us-gaap |
Profit Loss
ProfitLoss
|
-3813800 | usd |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-6177784 | usd |
CY2023 | sxtp |
Unrealized Foreign Currency Translation Gain Loss
UnrealizedForeignCurrencyTranslationGainLoss
|
61853 | usd |
CY2022 | sxtp |
Unrealized Foreign Currency Translation Gain Loss
UnrealizedForeignCurrencyTranslationGainLoss
|
-2127 | usd |
CY2023 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-3751947 | usd |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-6179911 | usd |
CY2023 | us-gaap |
Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
|
-48098 | usd |
CY2022 | us-gaap |
Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
|
3936 | usd |
CY2023 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3703849 | usd |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6183847 | usd |
CY2023 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
220714 | usd |
CY2023 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3924563 | usd |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6183847 | usd |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.99 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.61 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
3960280 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2367729 | shares |
CY2021Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-18154484 | usd |
CY2022 | us-gaap |
Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
|
29265 | usd |
CY2022 | sxtp |
Netloss Income Through May Thirty First Two Thousand Twenty Two
NetlossIncomeThroughMayThirtyFirstTwoThousandTwentyTwo
|
-1947876 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
185335 | usd |
CY2022 | sxtp |
Net Foreign Translation Gainloss After June One Two Thousand Twenty Two
NetForeignTranslationGainlossAfterJuneOneTwoThousandTwentyTwo
|
-27138 | usd |
CY2022 | sxtp |
Netloss Income After June One Two Thousand Twenty Two
NetlossIncomeAfterJuneOneTwoThousandTwentyTwo
|
-4229908 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-24149060 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-24149060 | usd |
CY2023 | sxtp |
Sharebased Compensation To Vendors For Services
SharebasedCompensationToVendorsForServices
|
5683056 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
7989598 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
|
10128500 | usd |
CY2023 | us-gaap |
Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
|
838748 | usd |
CY2023 | sxtp |
Net Of Underwriting Discounts And Offering Costs
NetOfUnderwritingDiscountsAndOfferingCosts
|
1266740 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
6235276 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1131771 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
528926 | usd |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
163228 | usd |
CY2023 | us-gaap |
Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
|
-61853 | usd |
CY2023 | us-gaap |
Profit Loss
ProfitLoss
|
-3813800 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
4798096 | usd |
CY2023 | us-gaap |
Profit Loss
ProfitLoss
|
-3813800 | usd |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-6177784 | usd |
CY2023 | us-gaap |
Depreciation
Depreciation
|
21162 | usd |
CY2022 | us-gaap |
Depreciation
Depreciation
|
27648 | usd |
CY2023 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
29157 | usd |
CY2022 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
5118 | usd |
CY2023 | sxtp |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
669148 | usd |
CY2022 | sxtp |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
1090387 | usd |
CY2023 | sxtp |
Amortization Of Rou Asset
AmortizationOfROUAsset
|
-50053 | usd |
CY2022 | sxtp |
Amortization Of Rou Asset
AmortizationOfROUAsset
|
-46020 | usd |
CY2023 | sxtp |
Amortization Of Note Issuance Costs
AmortizationOfNoteIssuanceCosts
|
-67728 | usd |
CY2022 | sxtp |
Amortization Of Note Issuance Costs
AmortizationOfNoteIssuanceCosts
|
-74496 | usd |
CY2023 | sxtp |
Amortization Of Capitalized Services
AmortizationOfCapitalizedServices
|
-994643 | usd |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
212605 | usd |
CY2023 | sxtp |
Share Based Compensation Under2022 Equity Incentive Plan
ShareBasedCompensationUnder2022EquityIncentivePlan
|
528926 | usd |
CY2023 | sxtp |
Deemed Capital Contribution For Related Party Compensation Expense Note11
DeemedCapitalContributionForRelatedPartyCompensationExpenseNote11
|
163228 | usd |
CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-1231480 | usd |
CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
120683 | usd |
CY2023 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
37278 | usd |
CY2022 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
10312 | usd |
CY2023 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
399725 | usd |
CY2022 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
504613 | usd |
CY2023 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-5379269 | usd |
CY2023 | us-gaap |
Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
|
-160338 | usd |
CY2022 | us-gaap |
Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
|
160338 | usd |
CY2023 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
185367 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-100397 | usd |
CY2023 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
522370 | usd |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-24902 | usd |
CY2023 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-212747 | usd |
CY2022 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-10126 | usd |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-214734 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
169990 | usd |
CY2023 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-1265361 | usd |
CY2022 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-2685678 | usd |
CY2023 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-50273 | usd |
CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-46795 | usd |
CY2023 | us-gaap |
Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
|
-100000 | usd |
CY2022 | us-gaap |
Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
|
425257 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4542910 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1009980 | usd |
CY2023 | us-gaap |
Payments For Software
PaymentsForSoftware
|
39982 | usd |
CY2022 | us-gaap |
Payments For Software
PaymentsForSoftware
|
33063 | usd |
CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
57623 | usd |
CY2023 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
18283 | usd |
CY2022 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
27070 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-115888 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-60133 | usd |
CY2023 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
150420 | usd |
CY2022 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
68629 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1047692 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1047692 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
6454325 | usd |
CY2023 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1131771 | usd |
CY2023 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
650000 | usd |
CY2022 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
800000 | usd |
CY2022 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
305000 | usd |
CY2023 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
1611111 | usd |
CY2023 | us-gaap |
Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
|
250000 | usd |
CY2022 | us-gaap |
Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
|
185335 | usd |
CY2023 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
250000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6474565 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1221706 | usd |
CY2023 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-61853 | usd |
CY2022 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
2127 | usd |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
1877620 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
149466 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
264865 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
115399 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2142485 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
264865 | usd |
CY2023 | us-gaap |
Interest Paid Net
InterestPaidNet
|
179117 | usd |
CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2193 | usd |
CY2023 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
1000 | usd |
CY2022 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
1000 | usd |
CY2023 | us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
7989598 | usd |
CY2022 | sxtp |
Conversion Of Related Party Advance Into Common Stock
ConversionOfRelatedPartyAdvanceIntoCommonStock
|
185335 | usd |
CY2023 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
10128500 | usd |
CY2023 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
270460 | usd |
CY2023 | sxtp |
Capitalized Share Based Payments To Vendors
CapitalizedShareBasedPaymentsToVendors
|
4916555 | usd |
CY2023 | sxtp |
Additions To Rou Assets For Lease Renewal
AdditionsToROUAssetsForLeaseRenewal
|
50922 | usd |
CY2023 | sxtp |
Additions To Lease Liabilities For Lease Renewal
AdditionsToLeaseLiabilitiesForLeaseRenewal
|
50570 | usd |
CY2022 | sxtp |
Conversion Of60 Pllc Member Units To Common Stock
ConversionOf60PLLCMemberUnitsToCommonStock
|
4979365 | usd |
CY2023 | sxtp |
Debt Discount Recorded In Connection With Derivative Liabilities
DebtDiscountRecordedInConnectionWithDerivativeLiabilities
|
650000 | usd |
CY2022 | sxtp |
Debt Discount Recorded In Connection With Derivative Liabilities
DebtDiscountRecordedInConnectionWithDerivativeLiabilities
|
1105000 | usd |
CY2023 | us-gaap |
Stock Issued1
StockIssued1
|
520000 | usd |
CY2023 | sxtp |
Stock Issued For Acquisition Of Intangibles
StockIssuedForAcquisitionOfIntangibles
|
33895 | usd |
CY2023 | us-gaap |
Notes Issued1
NotesIssued1
|
301416 | usd |
CY2023 | sxtp |
Reclassification Of Liabilityclassified Warrants To Equityclassified
ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified
|
-838748 | usd |
CY2023 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. NATURE OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Initial Public Offering</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants are immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 Tradeable Warrants at a price of $0.01 per Tradeable Warrant and/or 212,265 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination thereof (the “Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 100,644 Tradeable Warrants and 100,644 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 84,906 shares of the Company’s common stock, at an exercise price of $5.83 per share, equal to 110% of the offering price per unit (the “Representative Warrants”). The Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. See Note 6 for further details.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks and Uncertainties</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company’s ability to pursue its business strategy.<b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of these matters, continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from their single marketed product. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023, the Company had cash and cash equivalents totaling $2,142,485, as compared to cash and cash equivalents totaling $264,865 at December 31, 2022. During the twelve months ended December 31, 2023, the Company used cash of $4,542,910 in its operating activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. The Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these consolidated financial statements. As such, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt about the Company’s ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also expects to use cash and cash equivalents to fund activities relating to commercial support for its existing product and any future clinical research trials and operating activities. The Company’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s capital commitments over the next twelve months include interest obligations on the Company’s debt arrangements of $8,772, $13,650 for payments due under operating lease liabilities, and $506,206 to satisfy accounts payable and accrued expenses.</p> | |
CY2023Q3 | sxtp |
Percentage Of Offering Price Per Unit
PercentageOfOfferingPricePerUnit
|
1.10 | pure |
CY2023Q4 | us-gaap |
Cash
Cash
|
2142485 | usd |
CY2022Q4 | us-gaap |
Cash
Cash
|
264865 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4542910 | usd |
CY2023Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Current
SBAEIDLincludingAccruedInterestCurrent
|
8772 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
13650 | usd |
CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
506206 | usd |
CY2023Q4 | us-gaap |
Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee
EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee
|
1 | pure |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Use of Estimates</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset.</p> | |
CY2023Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | usd |
CY2023 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
191111 | usd |
CY2022 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
162222 | usd |
CY2023Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
2306796 | usd |
CY2023 | us-gaap |
Taxes Other
TaxesOther
|
250 | usd |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Concentrations</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant customers represent any customer whose business makes up 10% of receivables or revenues. At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively) and 93% of total net revenues (consisting of two significant customers at 72% and 21%, respectively). At December 31, 2022, 96% of the Company’s receivables (consisting of three customers and two significant customers at 66% and 30%), and 100% of total net revenues (consisting of four customers and three significant at 40%, 39% and 14%, respectively).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended in 2022 and near-term receivables and revenues from the government are not currently anticipated to be significant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company.</p> | |
CY2023 | us-gaap |
Related Party Transaction Rate
RelatedPartyTransactionRate
|
0 | pure |
CY2022 | us-gaap |
Related Party Transaction Rate
RelatedPartyTransactionRate
|
0.85 | pure |
CY2023 | us-gaap |
Revenue Recognition Allowances
RevenueRecognitionAllowances
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Revenue Recognition</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.</p> | |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
691770 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
525563 | usd |
CY2023Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
2306796 | usd |
CY2022Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
1494200 | usd |
CY2022Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
1494200 | usd |
CY2023 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Reclassifications</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ equity (deficit), or cash flows.</p> | |
CY2022Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
397487 | usd |
CY2023Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
278987 | usd |
CY2022Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
97486 | usd |
CY2023Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
187182 | usd |
CY2022Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
183943 | usd |
CY2023Q4 | us-gaap |
Inventory Gross
InventoryGross
|
466169 | usd |
CY2022Q4 | us-gaap |
Inventory Gross
InventoryGross
|
678916 | usd |
CY2022Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
160338 | usd |
CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
466169 | usd |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
518578 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
205825 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
148202 | usd |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
148064 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
126902 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
57761 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
21300 | usd |
CY2023 | us-gaap |
Depreciation
Depreciation
|
21162 | usd |
CY2022 | us-gaap |
Depreciation
Depreciation
|
27648 | usd |
CY2023Q4 | us-gaap |
Finite Lived Patents Gross
FiniteLivedPatentsGross
|
185595 | usd |
CY2022Q4 | us-gaap |
Finite Lived Patents Gross
FiniteLivedPatentsGross
|
145613 | usd |
CY2023Q4 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
79248 | usd |
CY2022Q4 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
27070 | usd |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
264843 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
172683 | usd |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
37585 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
8428 | usd |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
227258 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
164255 | usd |
CY2023 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
29157 | usd |
CY2022 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
5118 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
|
93545 | usd |
CY2022Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
5 | |
CY2022Q4 | sxtp |
Percentage Of Share Issued And Outstanding
PercentageOfShareIssuedAndOutstanding
|
0.61 | pure |
CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
31447 | shares |
CY2023Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
31447 | shares |
CY2023Q3 | us-gaap |
Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
|
214934 | shares |
CY2023Q3 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
45560 | shares |
CY2022Q2 | sxtp |
Bridge Warrants Exercisable Into Common Stock
BridgeWarrantsExercisableIntoCommonStock
|
231917 | shares |
CY2023Q2 | sxtp |
Bridge Warrants Exercisable Into Common Stock
BridgeWarrantsExercisableIntoCommonStock
|
231917 | shares |
CY2022Q2 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
151991 | shares |
CY2023Q2 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
151991 | shares |
CY2022Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.83 | |
CY2023Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.83 | |
CY2022Q2 | sxtp |
Percentage Of Ipo Price
PercentageOfIPOPrice
|
1.10 | pure |
CY2023Q2 | sxtp |
Percentage Of Ipo Price
PercentageOfIPOPrice
|
1.10 | pure |
CY2023 | us-gaap |
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
|
1131771 | usd |
CY2023 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
|
0 | pure |
CY2023 | us-gaap |
Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
|
0.06 | pure |
CY2020Q4 | us-gaap |
Other Deferred Costs Gross
OtherDeferredCostsGross
|
100000 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Cashbased Arrangements Liability Classified Noncurrent
DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent
|
60000 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
|
400000 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Cash Based Arrangements Liability Current
DeferredCompensationCashBasedArrangementsLiabilityCurrent
|
100000 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Equity
DeferredCompensationEquity
|
245000 | usd |
CY2022Q2 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
100000 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
|
57198 | usd |
CY2022Q2 | us-gaap |
Compensated Absences Liability
CompensatedAbsencesLiability
|
12500 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage
DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
|
1 | pure |
CY2022Q2 | us-gaap |
Deferred Compensation Cash Based Arrangements Liability Current
DeferredCompensationCashBasedArrangementsLiabilityCurrent
|
38900 | usd |
CY2022Q2 | us-gaap |
Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
|
60000 | usd |
CY2022 | us-gaap |
Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
|
65000 | shares |
CY2022 | us-gaap |
Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
|
5 | |
CY2022Q4 | us-gaap |
Deferred Compensation Arrangement With Individual Recorded Liability
DeferredCompensationArrangementWithIndividualRecordedLiability
|
325000 | usd |
CY2023Q1 | us-gaap |
Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
|
65000 | shares |
CY2022Q4 | us-gaap |
Loans Payable
LoansPayable
|
20596595 | usd |
CY2023 | us-gaap |
Long Term Debt Maturities Repayment Terms
LongTermDebtMaturitiesRepaymentTerms
|
30 days | |
CY2023Q4 | us-gaap |
Shortterm Debt Fair Value
ShorttermDebtFairValue
|
120683 | usd |
CY2023 | us-gaap |
Interest Costs Incurred
InterestCostsIncurred
|
1767 | usd |
CY2023 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
52628 | usd |
CY2022 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4955 | usd |
CY2023 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
66558 | usd |
CY2022 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
115546 | usd |
CY2022Q1 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
214934 | shares |
CY2022Q1 | us-gaap |
Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
|
223077 | usd |
CY2022Q4 | us-gaap |
Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
|
17965670 | usd |
CY2022Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
16855887 | usd |
CY2022Q4 | us-gaap |
Senior Long Term Notes
SeniorLongTermNotes
|
1109783 | usd |
CY2023 | us-gaap |
Extinguishment Of Debt Gain Loss Income Tax
ExtinguishmentOfDebtGainLossIncomeTax
|
614670 | usd |
CY2023Q2 | us-gaap |
Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
|
8472 | usd |
CY2023Q2 | us-gaap |
Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
|
0.90 | pure |
CY2023 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
79926 | shares |
CY2023 | sxtp |
Initial Public Offering Discount Percentages
InitialPublicOfferingDiscountPercentages
|
0.15 | pure |
CY2023 | sxtp |
Common Stock Outstanding Percentages
CommonStockOutstandingPercentages
|
0.199 | pure |
CY2023 | us-gaap |
Payments For Fees
PaymentsForFees
|
10000000 | usd |
CY2023 | us-gaap |
Management Fee Expense
ManagementFeeExpense
|
30000 | usd |
CY2023Q4 | sxtp |
Cumulative Dividend Percentage
CumulativeDividendPercentage
|
0.06 | pure |
CY2023Q4 | sxtp |
Common Stock Ownership Percentage
CommonStockOwnershipPercentage
|
0.199 | pure |
CY2022Q1 | sxtp |
Equal Royalty Pay To Lender Percentage
EqualRoyaltyPayToLenderPercentage
|
3.5 | usd |
CY2023Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
839887 | usd |
CY2023Q4 | us-gaap |
Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
|
21520650 | usd |
CY2023 | us-gaap |
Assets Fair Value Adjustment
AssetsFairValueAdjustment
|
-5379269 | usd |
CY2023 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1293549 | usd |
CY2023 | us-gaap |
Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
|
17434930 | usd |
CY2023 | sxtp |
Description Of Knight Debt Conversion Agreement
DescriptionOfKnightDebtConversionAgreement
|
As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,105,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment. | |
CY2019Q2 | us-gaap |
Debt Current
DebtCurrent
|
3000000 | usd |
CY2019Q2 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
2100000 | usd |
CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
0 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
279061 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
3000000 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
279061 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
|
2720939 | usd |
CY2022Q4 | us-gaap |
Accumulated Capitalized Interest Costs
AccumulatedCapitalizedInterestCosts
|
1555670 | usd |
CY2022Q4 | us-gaap |
Other Long Term Debt Current
OtherLongTermDebtCurrent
|
4276609 | usd |
CY2022Q4 | us-gaap |
Interest Paid Net
InterestPaidNet
|
731 | usd |
CY2023Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Current
SBAEIDLincludingAccruedInterestCurrent
|
8772 | usd |
CY2023Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
150251 | usd |
CY2022Q4 | us-gaap |
Debt Securities Held To Maturity Fair Value Current
DebtSecuritiesHeldToMaturityFairValueCurrent
|
2750 | usd |
CY2022Q4 | sxtp |
Sbaeid Lincluding Accrued Interest Non Current
SBAEIDLincludingAccruedInterestNonCurrent
|
160272 | usd |
CY2023Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
683 | usd |
CY2023Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
3228 | usd |
CY2023Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
3342 | usd |
CY2023Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
|
142747 | usd |
CY2023Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
150000 | usd |
CY2023Q1 | us-gaap |
Other Short Term Investments
OtherShortTermInvestments
|
200000 | usd |
CY2023Q2 | us-gaap |
Other Short Term Investments
OtherShortTermInvestments
|
50000 | usd |
CY2023Q2 | us-gaap |
Other Short Term Investments
OtherShortTermInvestments
|
250000 | usd |
CY2022Q2 | us-gaap |
Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
|
1483888 | usd |
CY2022Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
979275 | usd |
CY2022Q2 | us-gaap |
Derivative Cost Of Hedge
DerivativeCostOfHedge
|
504613 | usd |
CY2023Q2 | us-gaap |
Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
|
954725 | usd |
CY2023Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
555000 | usd |
CY2023Q2 | us-gaap |
Derivative Cost Of Hedge
DerivativeCostOfHedge
|
399725 | usd |
CY2022Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
1494200 | usd |
CY2023 | sxtp |
Fair Value Mark To Market Adjustment
FairValueMarkToMarketAdjustment
|
-2834 | usd |
CY2023 | sxtp |
Fair Value Commitment Date
FairValueCommitmentDate
|
954725 | usd |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
-149542 | usd |
CY2023Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
1457801 | usd |
CY2023 | sxtp |
Reclassification Of Liabilityclassified Warrants To Equityclassified
ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified
|
-838748 | usd |
CY2023 | sxtp |
Derivative Instrument Recognition Of Contingent Milestone Liability
DerivativeInstrumentRecognitionOfContingentMilestoneLiability
|
2117142 | usd |
CY2023 | sxtp |
Fair Value Mark To Market Adjustment Contingent Milestone Payment
FairValueMarkToMarketAdjustmentContingentMilestonePayment
|
189654 | usd |
CY2023Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
2306796 | usd |
CY2022 | sxtp |
Fair Value Commitment Date
FairValueCommitmentDate
|
1483888 | usd |
CY2022 | sxtp |
Fair Value Mark To Market Adjustment
FairValueMarkToMarketAdjustment
|
10312 | usd |
CY2022Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
1494200 | usd |
CY2023Q4 | us-gaap |
Price Risk Derivative Liabilities At Fair Value
PriceRiskDerivativeLiabilitiesAtFairValue
|
37278 | usd |
CY2022Q4 | us-gaap |
Price Risk Derivative Liabilities At Fair Value
PriceRiskDerivativeLiabilitiesAtFairValue
|
10312 | usd |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-3006861 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-5807367 | usd |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-806689 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-369917 | usd |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3813550 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6177284 | usd |
CY2023 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
250 | usd |
CY2022 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
500 | usd |
CY2023 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
250 | usd |
CY2022 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
500 | usd |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
250 | usd |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
500 | usd |
CY2023 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-800846 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | pure |
CY2022 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1297230 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | pure |
CY2023 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-364618 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.096 | pure |
CY2022 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-478515 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.077 | pure |
CY2023 | sxtp |
Effective Income Tax Rate Reconcilation Impact Of Non Us Earnings Amount
EffectiveIncomeTaxRateReconcilationImpactOfNonUSEarningsAmount
|
-33994 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.009 | pure |
CY2022 | sxtp |
Effective Income Tax Rate Reconcilation Impact Of Non Us Earnings Amount
EffectiveIncomeTaxRateReconcilationImpactOfNonUSEarningsAmount
|
-33897 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.005 | pure |
CY2023 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
280654 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.074 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | pure |
CY2023 | us-gaap |
Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
|
1129646 | usd |
CY2023 | sxtp |
Effective Income Tax Rate Reconciliation Change In Fair Value Of Promissory Note Rate
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPromissoryNoteRate
|
0.296 | pure |
CY2022 | sxtp |
Effective Income Tax Rate Reconciliation Change In Fair Value Of Promissory Note Rate
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPromissoryNoteRate
|
0 | pure |
CY2023 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
304962 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
-0.08 | pure |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0 | pure |
CY2023 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
2042657 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
-0.536 | pure |
CY2022 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
683359 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
-0.111 | pure |
CY2023 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-298919 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.078 | pure |
CY2022 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1126783 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.182 | pure |
CY2023 | sxtp |
Tax Reconciliation Not Required
TaxReconciliationNotRequired
|
250 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.001 | pure |
CY2022 | sxtp |
Tax Reconciliation Not Required
TaxReconciliationNotRequired
|
500 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.001 | pure |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
3453126 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
3338726 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
|
1058 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
189893 | usd |
CY2023Q4 | sxtp |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
3756 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
94034 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
3741867 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
3338726 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3043135 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3338726 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
698732 | usd |
CY2023Q4 | sxtp |
Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
|
-3719 | usd |
CY2023Q4 | sxtp |
Deferred Tax Liabilitie Prepaid Expenses
DeferredTaxLiabilitiePrepaidExpenses
|
695013 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
698732 | usd |
CY2023 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
295591 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
6339101 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
6338851 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
5807867 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
5807367 | usd |
CY2023 | sxtp |
Annual Taxable Income
AnnualTaxableIncome
|
0.80 | pure |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
|
6835123 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
|
6560235 | usd |
CY2023 | us-gaap |
Other Research And Development Expense
OtherResearchAndDevelopmentExpense
|
192371 | usd |
CY2023 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
1543803 | usd |
CY2023 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
1736174 | usd |
CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
|
187200 | usd |
CY2023Q3 | us-gaap |
Deferred Compensation Arrangement With Individual Shares Authorized For Issuance
DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
|
40000 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.16 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0433 | pure |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.10 | pure |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y2M4D | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
119246 | usd |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | usd |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
|
740000 | shares |
CY2023Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
5.3 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
256000 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.87 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
256000 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
0.87 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
|
256000 | shares |
CY2023Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
222480 | usd |
CY2023 | us-gaap |
Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
|
256000 | shares |
CY2023 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
776471 | shares |
CY2022 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
0 | shares |
CY2023Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
242647 | usd |
CY2023 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
163228 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.15 | pure |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
13992 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
13992 | usd |
CY2023Q4 | us-gaap |
Receivable With Imputed Interest Discount
ReceivableWithImputedInterestDiscount
|
342 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
13650 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
13650 | usd |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P0Y3M | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.15 | pure |
CY2023 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
55084 | usd |
CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
51894 | usd |
CY2023Q3 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
9434 | shares |
CY2015Q3 | sxtp |
Licensed Technology Term
LicensedTechnologyTerm
|
P20Y | |
CY2015Q3 | sxtp |
Annual Royalty Payment Percentage
AnnualRoyaltyPaymentPercentage
|
0.05 | pure |
CY2015Q3 | us-gaap |
Sales Commissions And Fees
SalesCommissionsAndFees
|
75000 | usd |
CY2015Q3 | us-gaap |
Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
|
6000000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
|
75000 | usd |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
|
789136 | shares |
CY2023Q4 | us-gaap |
Share Price
SharePrice
|
0.385 | |
CY2023 | sxtp |
Pre Funded Warrants
PreFundedWarrants
|
149862 | shares |
CY2023 | sxtp |
Pre Funded Warrants Per Price
PreFundedWarrantsPerPrice
|
0.375 | |
CY2023 | sxtp |
Percentage Of Warrants Underlying Units
PercentageOfWarrantsUnderlyingUnits
|
0.15 | pure |
CY2023 | sxtp |
Percentage Of Common Shares
PercentageOfCommonShares
|
0.06 | pure |
CY2023 | sxtp |
Percentage Of Offering Price Per Unit
PercentageOfOfferingPricePerUnit
|
1.10 | pure |
CY2023 | us-gaap |
Underwriting Income Loss
UnderwritingIncomeLoss
|
1900000 | usd |
CY2023Q4 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
CY2023Q4 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2023Q4 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2023Q4 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
CY2022Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
usd | |
CY2023Q4 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
usd | |
CY2023Q4 | sxtp |
Related Party Notes Netincluding Accrued Interest
RelatedPartyNotesNetincludingAccruedInterest
|
usd | |
CY2023Q4 | us-gaap |
Other Long Term Debt Current
OtherLongTermDebtCurrent
|
usd | |
CY2023Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
usd | |
CY2023Q4 | sxtp |
Derivative Liabilities Related Parties
DerivativeLiabilitiesRelatedParties
|
usd | |
CY2023Q4 | us-gaap |
Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
|
usd | |
CY2023Q4 | us-gaap |
Senior Long Term Notes
SeniorLongTermNotes
|
usd | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
CY2023 | us-gaap |
Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
|
usd | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.99 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2367729 | shares |
CY2022 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
usd | |
CY2023 | sxtp |
Cancellation Of Common Stock
CancellationOfCommonStock
|
usd | |
CY2023 | sxtp |
Voluntary Conversion Of Series A Preferred Stock Into Common Stock
VoluntaryConversionOfSeriesAPreferredStockIntoCommonStock
|
usd | |
CY2023 | sxtp |
Contribution From Noncontrolling Interest
ContributionFromNoncontrollingInterest
|
usd | |
CY2022 | sxtp |
Amortization Of Capitalized Services
AmortizationOfCapitalizedServices
|
usd | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
usd | |
CY2022 | sxtp |
Share Based Compensation Under2022 Equity Incentive Plan
ShareBasedCompensationUnder2022EquityIncentivePlan
|
usd | |
CY2022 | sxtp |
Deemed Capital Contribution For Related Party Compensation Expense Note11
DeemedCapitalContributionForRelatedPartyCompensationExpenseNote11
|
usd | |
CY2022 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
usd | |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
usd | |
CY2022 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
usd | |
CY2022 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
usd | |
CY2023 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
usd | |
CY2022 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
usd | |
CY2022 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
usd | |
CY2022 | us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
usd | |
CY2023 | sxtp |
Conversion Of Related Party Advance Into Common Stock
ConversionOfRelatedPartyAdvanceIntoCommonStock
|
usd | |
CY2022 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
usd | |
CY2022 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
usd | |
CY2022 | sxtp |
Capitalized Share Based Payments To Vendors
CapitalizedShareBasedPaymentsToVendors
|
usd | |
CY2022 | sxtp |
Additions To Rou Assets For Lease Renewal
AdditionsToROUAssetsForLeaseRenewal
|
usd | |
CY2022 | sxtp |
Additions To Lease Liabilities For Lease Renewal
AdditionsToLeaseLiabilitiesForLeaseRenewal
|
usd | |
CY2023 | sxtp |
Conversion Of60 Pllc Member Units To Common Stock
ConversionOf60PLLCMemberUnitsToCommonStock
|
usd | |
CY2022 | us-gaap |
Stock Issued1
StockIssued1
|
usd | |
CY2022 | sxtp |
Stock Issued For Acquisition Of Intangibles
StockIssuedForAcquisitionOfIntangibles
|
usd | |
CY2022 | us-gaap |
Notes Issued1
NotesIssued1
|
usd | |
CY2022 | sxtp |
Reclassification Of Liabilityclassified Warrants To Equityclassified
ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified
|
usd | |
CY2023Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
usd | |
CY2023Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
usd | |
CY2023Q4 | us-gaap |
Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
|
usd | |
CY2023Q4 | us-gaap |
Notes Payable
NotesPayable
|
usd | |
CY2023Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
usd | |
CY2023Q4 | us-gaap |
Senior Long Term Notes
SeniorLongTermNotes
|
usd | |
CY2022Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
usd | |
CY2023Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
usd | |
CY2023Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
usd | |
CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
usd | |
CY2023Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
|
usd | |
CY2023Q4 | us-gaap |
Accumulated Capitalized Interest Costs
AccumulatedCapitalizedInterestCosts
|
usd | |
CY2023Q4 | us-gaap |
Other Long Term Debt Current
OtherLongTermDebtCurrent
|
usd | |
CY2023Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
usd | |
CY2023Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
usd | |
CY2021Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
usd | |
CY2023Q4 | us-gaap |
Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
|
http://fasb.org/us-gaap/2023#DerivativeLiabilitiesCurrent | |
CY2023 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
usd | |
CY2023 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
usd | |
CY2023 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
usd | |
CY2023 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
usd | |
CY2023 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
usd | |
CY2023 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
usd | |
CY2022 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
usd | |
CY2022 | us-gaap |
Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
|
usd | |
CY2022 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
usd | |
CY2022Q4 | sxtp |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
usd | |
CY2022Q4 | sxtp |
Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
|
usd | |
CY2022Q4 | sxtp |
Deferred Tax Liabilitie Prepaid Expenses
DeferredTaxLiabilitiePrepaidExpenses
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
usd | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
usd | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
usd | |
CY2022 | us-gaap |
Other Research And Development Expense
OtherResearchAndDevelopmentExpense
|
usd | |
CY2022 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
usd | |
CY2022 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
usd | |
CY2022Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
shares | |
CY2022Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
||
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
shares | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
||
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
shares | |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
||
CY2022Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
usd | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
usd | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
usd | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent | |
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001946563 |